Beaumont V, Lemort N, Doucet F, Beaumont J L
Atherosclerosis. 1985 Dec;58(1-3):243-59. doi: 10.1016/0021-9150(85)90069-3.
Recent epidemiological data indicate that the risk of thromboembolic disease associated with oral contraception (OC) may persist after discontinuation of the drug. It was demonstrated on the other hand that antibodies to sex steroid hormones which develop in OC users, were significantly correlated with the incidence of thrombosis. It is well known that antibodies may persist years after the antigenic stimulation. So it was of interest to see if the eventual occurrence of thrombosis in ex-users might be correlated with the presence of anti-sex steroid antibodies remaining after stopping OC. Thirty-eight women with thrombosis on OC and positive antibody levels, who were required to stop the pill, were followed for periods ranging from 1 to 10 years. No disappearance of anti-ethinyl-estradiol antibodies (anti-EE ab) was observed except for 2 cases. On the other hand, 109 patients with thrombosis either current- (50), past- (29), or never-users (30) of OC were compared to 102 controls of similar groups. Results indicate that the levels of anti-EE ab, and the percentage of women who had anti-EE ab, were similar in those who experienced thrombosis either in the course of OC or after discontinuation. A significant difference was observed between both cases who were current- or ex-users and their controls.
近期流行病学数据表明,与口服避孕药(OC)相关的血栓栓塞性疾病风险在停药后可能依然存在。另一方面,有证据表明,口服避孕药使用者体内产生的抗性激素抗体与血栓形成的发生率显著相关。众所周知,抗体在抗原刺激后可能会持续存在数年。因此,探究停用口服避孕药后使用者最终发生血栓形成是否与残留的抗性激素抗体有关,是很有意义的。38名正在服用口服避孕药且抗体水平呈阳性、后被要求停药的血栓形成女性,接受了为期1至10年的随访。除2例患者外,未观察到抗乙炔雌二醇抗体(anti-EE ab)消失。另一方面,将109例有血栓形成的患者(其中正在服用口服避孕药的50例、过去服用过口服避孕药的29例、从未服用过口服避孕药的30例)与102例类似组别的对照者进行了比较。结果表明,在口服避孕药期间或停药后发生血栓形成的患者中,抗乙炔雌二醇抗体水平以及有抗乙炔雌二醇抗体的女性比例相似。正在服用或曾经服用口服避孕药的患者与其对照者之间观察到了显著差异。